In The News
Katy Perry wins appeal in trade mark fight with Aussie designer
Lawyers in NSW can’t use AI to generate affidavits, witness statements, court says
Group members get nothing in RoundUp class action settlement
Second judge has rosier view of claims in class action over $85M development
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Law firm report clears WiseTech founder Richard White of misconduct
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
US has immunity from Darwin-based soldier’s personal injury suit: court
Clyde & Co sued by insurers over indemnity advice
Russells partner accused of bullying told lawyer she was ‘very negative’
Please login to bookmarkClose

Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au